Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location (MAGELLAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04925583
Recruitment Status : Not yet recruiting
First Posted : June 14, 2021
Last Update Posted : September 29, 2021
Sponsor:
Information provided by (Responsible Party):
Juergen Debus, University Hospital Heidelberg

Brief Summary:

MAGELLAN is a phase-I dose escalation trial that aims to identify the maximum tolerated dose (MTD) of MR-guided SBRT of ultracentral lung Tumors (primary objective). Thus, a maximum of 38 patients with ultracentral lung tumors (overlap of the planning target volume with the proximal bronchial tree and/or esophagus) will receive MR-guided SBRT including gated dose delivery and daily plan adaptation on a 0.35 MR-linac System. Dose levels are as follows:

  • 0 (de-escalation): 10 x 5.0Gy
  • 1 (start): 10 x 5.5Gy
  • 2: 10 x 6.0Gy
  • 3: 10 x 6.5Gy

Dose escalation is performed according to a time-to-event continual reassessment method (TITE-CRM) with backup element. Patients are observed individually for 12 months to detect potential dose limiting toxicity (DLT = primary endpoint) and for a total of 24 months to detect potential tumor relapse.


Condition or disease Intervention/treatment Phase
Lung Cancer Radiation: Stereotactic body radiotherapy (SBRT) Phase 1

Detailed Description:

Stereotactic body radiotherapy (SBRT) is a well-established local treatment method for early-stage NSCLC or lung metastases. However, clinicians are restricted in the utilization of sufficiently high radiation doses when the lung tumor is in ultracentral location next to radiosensitive organs-at-risk (OAR, e.g. the central airways or the esophagus). MR-guided SBRT can minimize the dose to these OAR by advanced techniques to correct for interfractional (daily plan adaptation) and intrafractional motion (respiratory gating, i.e. synchronization of beam delivery to the patient's breathing). Consequently, the MAGELLAN trial uses MR-guided SBRT to enable safe dose escalation to ultracentral lung tumors. The primary objective of this phase I dose escalation trial is to detect the maximum tolerated dose of MR-guided SBRT to ultracentral lung tumors with a dose limiting toxicity (DLT) rate = 35%. This dose should yield the optimum balance between acceptable treatment toxicity and good tumor control. The corresponding primary endpoint is the observation of the binary outcome dose-limiting toxicity (DLT) within 12 months from start of radiation. Secondary objectives include description of tumor control, patient survival and patient-reported outcomes, assessment of longitudinal cardiopulmonary function and dosimetry evaluations. Exploratory objectives include detection of early biomarkers of pulmonary toxicity and tumor response from multiparamtetric thoracic MRI examinations as well as peripheral blood samples before and early after treatment. A maximum of 38 adult patients may be accrued. Inclusion criteria encompass indication for pulmonary SBRT, ultracentral lung tumor location defined as overlap of the planning target volume (PTV) with the proximal bronchial tree or esophagus and a maximum tumor diameter ≤ 5cm. MR-guided SBRT is delivered on a 0.35T MR-Linac (6MV linear accelerator) with daily plan adaptation and gated dose delivery. Four dose levels may be employed:

  • 0 (de-escalation): 10 x 5.0Gy
  • 1 (start): 10 x 5.5Gy
  • 2: 10 x 6.0Gy
  • 3: 10 x 6.5Gy

Dose level 0 represents a de-escalation step which is deemed safe by retrospective clinical data. Dose level 3 confidently reaches a BED10 > 100 Gy necessary for adequate local tumor control in the lung according to hitherto data. Individual observation time for DLTs is 12 months. Dose escalation is performed in dose escalation cohorts consisting of three patients (N = 3) and the first cohort starts at dose level 1 (10 x 5.5 Gy). A time-to-event continual reassessment method (TITE-CRM) is used to recommend the dose level for the next cohort after a cumulative observation time of 18 months. TITE-CRM accounts for all available data at any given time to estimate DLT rates for each dose level and will recommend the dose level closest to the MTD. Admissible patients who present during the cumulative observation time are included as backup patients and treated on the dose level below the current recommendation. An escalation with overdose control (EWOC) approach is applied to prevent treatment with too toxic doses. According to the stopping criteria, patient accrual will be stopped after including 36 patients or 40 months after the first subject in date (recruitment of current dose escalation cohort may be completed), in case that estimation of the MTD is sufficiently certain or if all dose levels appear too toxic. After patient accrual has been stopped and all patients have completed their individual observation time, a final dose recommendaton will be performed which represents the MTD estimate. During follow-up, patients receive clinical assessments (3 monthly), thoracic CT- (3-monthly) and MR-imaging (after 3 months), one cardiology assessment (after 12 months), pulmonary function testing (12-monthly) and peripheral blood samples (last treatment day, after 3 months) for a total of 2 years after treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 38 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: Dose escalation, Arm 1: Level 0, 5.0 Gy, 10 fractions Arm 2: Level 1, 5.5 Gy, 10 fractions Arm 3: Level 2, 6.0 Gy, 10 fractions Arm 4: Level 3, 6.5 Gy, 10 fractoins
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location
Estimated Study Start Date : November 1, 2021
Estimated Primary Completion Date : November 1, 2025
Estimated Study Completion Date : November 1, 2026

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Level 0
Total dose 50 Gy, (10 x 5 Gy single dose)
Radiation: Stereotactic body radiotherapy (SBRT)
  • level 0 (de-escalation): 10 x 5.0Gy
  • level 1 (start): 10 x 5.5Gy
  • level 2: 10 x 6.0Gy
  • level 3: 10 x 6.5Gy

Experimental: Level 1
Total dose 55 Gy, (10 x 5.5 Gy single dose)
Radiation: Stereotactic body radiotherapy (SBRT)
  • level 0 (de-escalation): 10 x 5.0Gy
  • level 1 (start): 10 x 5.5Gy
  • level 2: 10 x 6.0Gy
  • level 3: 10 x 6.5Gy

Experimental: Level 2
Total dose 60 Gy, (10 x 6 Gy single dose)
Radiation: Stereotactic body radiotherapy (SBRT)
  • level 0 (de-escalation): 10 x 5.0Gy
  • level 1 (start): 10 x 5.5Gy
  • level 2: 10 x 6.0Gy
  • level 3: 10 x 6.5Gy

Experimental: Level 3
Total dose 65 Gy, (10 x 6.5 Gy single dose)
Radiation: Stereotactic body radiotherapy (SBRT)
  • level 0 (de-escalation): 10 x 5.0Gy
  • level 1 (start): 10 x 5.5Gy
  • level 2: 10 x 6.0Gy
  • level 3: 10 x 6.5Gy




Primary Outcome Measures :
  1. Dose limiting toxicity (DLT) [ Time Frame: For 12 months from the beginning of SBRT. ]
    Observation of the binary outcome dose-limiting toxicity (DLT). DLTs are defined in a catalogue of mainly pulmonary, esophageal and cardiac toxicity based on the CTCAE in Version 5.0.


Secondary Outcome Measures :
  1. Local tumor control [ Time Frame: For 24 months upon enrollment ]
    Total number of treated ultracentral tumor.

  2. Regional tumor control [ Time Frame: For 24 months upon enrollment ]
    Number of tumor leasions in Lungs and Mediastinum excluding the treated ultracentral tumor.

  3. Distant tumor Control [ Time Frame: For 24 months upon enrollment ]
    Number of Tumor leasions Outside lungs and mediastinum.

  4. Progression-free survival [ Time Frame: For 24 months upon enrollment ]
  5. Overall survival [ Time Frame: For 24 months upon enrollment ]
  6. EORTC QLQ C-30 [ Time Frame: For 24 months upon enrollment ]
    Changes in quality of life following MR-guided ultracentral lung SBRT, according to EORTC QLQ C-30.

  7. EORTC QLQ-LC13 [ Time Frame: For 24 months upon enrollment ]
    Changes in quality of life following MR-guided ultracentral lung SBRT, according to EORTC QLQ-LC13.

  8. Vital Capacity [ Time Frame: For 24 months upon enrollment ]
    Pulmonary function test parameter.

  9. Forced Expiratory Volume in the 1st second [ Time Frame: For 24 months upon enrollment ]
    Pulmonary function test parameter.

  10. Cardiovascular function: Longitudinal strain [ Time Frame: For 12 months upon enrollment ]
    Echocardiography.

  11. Cardiovascular function: Left ventricular ejection fraction (LVEF) [ Time Frame: For 12 months upon enrollment ]
    Echocardiography.

  12. Cardiovascular function: Ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e') [ Time Frame: For 12 months upon enrollment ]
    Echocardiography.

  13. Cardiovascular function: N-terminal prohormone of brain natriuretic peptide (NT-proBNP) [ Time Frame: For 12 months upon enrollment ]
    Blood Sample.

  14. Cardiovascular function: High-sensitive Troponin-T (hsTNT) [ Time Frame: For 12 months upon enrollment ]
    Blood Sample.

  15. Dosimetry parameters of MRgRT as compared to CT-based SBRT techniques [ Time Frame: through study completion, an average of 1 year ]
  16. Apparent Diffusion Coefficient (ADC) [ Time Frame: 3 months upon SBRT. ]
    Translational imaging biomarkers based on multiparametric MRI (T1w, T2w and diffusion-weighted) for early detection of pulmonary toxicity and tumor relapse (explorative).

  17. Serum cytokines [ Time Frame: Immediately and 3 months upon SBRT. ]
    Translational blood biomarkers (explorative).

  18. Immunophenotypes of peripheral blood mononucleated cells (PBMC) [ Time Frame: Immediately and 3 months upon SBRT. ]
    Translational blood biomarkers for early detection of pulmonary toxicity and tumor relapse (explorative).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ultracentral location of the lung tumor, which is defined as an expected contact or overlap of the planning target volume with the proximal bronchial tree or esophagus at the time of consultation
  • indication for SBRT of the ultracentral pulmonary tumor
  • maximum diameter of the ultracentral pulmonary tumor < 5cm
  • age > 18 years of age
  • Karnofsky Performance Score > 70% (ECOG Score 0 - 2)
  • ability to lie still on the MR-linac table for at least one hour
  • ability to hold one's breath for more than 20 seconds
  • successful completion of MRgRT simulation
  • for women with childbearing potential, adequate contraception.
  • ability of subject to understand character and individual consequences of the clinical trial
  • written informed consent (must be available before enrolment in the trial)

Exclusion Criteria:

  • refusal of the patients to take part in the study
  • previous radiotherapy of the lung and mediastinum, if previous and current target volumes overlap
  • patients who have not yet recovered from acute toxicities of prior therapies
  • (planned) treatment with vascular endothelial growth factor (VEGF) inhibitors, e.g. Bevacizumab, within the time interval 2 weeks before and 2 weeks after SBRT
  • pregnant or lactating women
  • contraindications against performing MRI scans (pacemakers, other implants making MRI impossible)
  • participation in another competing clinical study or observation period of competing trials

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04925583


Contacts
Layout table for location contacts
Contact: Juliane Hörner-Rieber, PD +49 6221-56 ext 8201 Juliane.Hoerner-Rieber@med.uni-heidelberg.de
Contact: Adriane Hommertgen, PhD +49 6221 56 ext 8201 adriane.hommertgen@med.uni-heidelberg.de

Locations
Layout table for location information
Germany
University Hospital of Heidelberg, Radiation Oncology
Heidelberg, Germany, 69120
Sponsors and Collaborators
University Hospital Heidelberg
Investigators
Layout table for investigator information
Principal Investigator: Juliane Hörner-Rieber, PD University Hospital Heidelberg
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Juergen Debus, Department Head, University Hospital Heidelberg
ClinicalTrials.gov Identifier: NCT04925583    
Other Study ID Numbers: RADONK-Magellan_2020
First Posted: June 14, 2021    Key Record Dates
Last Update Posted: September 29, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Juergen Debus, University Hospital Heidelberg:
SBRT
IGRT
MR-guidance
ultracentral lung tumor
NSCLC
oligometastases
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases